IL10 and non-small cell lung carcinoma: By integrating these data with the results of the current work, we also observed that ALK + NSCLC patients that were treatment naive or at therapy baseline have significantly elevated serum IL-6, IL-8 and IL-10 levels compared to healthy controls (Supplementary Fig. 5).